The trajectory of Sildenafil presents a interesting case for observers in the medicinal sector. While initially a phenomenal success, generating billions, the patent lapse and the subsequent flood of off-brand versions have considerably affected income. This raises questions about the ongoing profitability of similar drug innovations and suggests t